Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Evernorth takes specialty pharmacy market share, PBM regulatory fears ease, and the multiple re-rates toward the 13x peer median.
PBM Spread Pricing Ban: Federal legislation permanently bans spread pricing and mandates full rebate pass-throughs across all books of business.
The Cigna Group acts as a highly cash-generative mature compounder, combining a resilient specialty pharmacy and PBM business (Evernorth) with traditional healthcare insurance. Currently trading at a discount to peers (8.6x forward P/E vs 13.06x median), it offers a compelling margin of safety if regulatory fears subside.
The Cigna Group acts as a highly cash-generative mature compounder, combining a resilient specialty pharmacy and PBM business (Evernorth) with traditional healthcare insurance. Currently trading at a discount to peers (8.6x forward P/E vs 13.06x median), it offers a compelling margin of safety if regulatory fears subside.
Evernorth scale and specialty pharmacy dominance
Vertical integration of PBM and health benefits
Consolidation of specialty pharmacy and managed care services driving scale efficiencies.
Strong conviction Strong Buy at $289.07 against a fair value of $561.36, offering 94% upside due to mispriced PBM regulatory overhang.
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Sweeping legislative changes target PBM spread pricing and rebates, crippling Evernorth's profitability. At the same time, sudden medical cost inflation squeezes traditional insurance margins, limiting the cash available to service Cigna's massive debt load.
Evernorth scale and specialty pharmacy dominance
Vertical integration of PBM and health benefits
High switching costs for enterprise clients
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $5.5B after capex $2.1B, with terminal value at 77.8% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
Focus on Evernorth margin stability and Medical Care Ratio (MCR) trends. Upside beats on specialty pharmacy volume drive multiple expansion.
Focus on Evernorth margin stability and Medical Care Ratio (MCR) trends. Upside beats on specialty pharmacy volume drive multiple expansion.
Focus on Evernorth margin stability and Medical Care Ratio (MCR) trends. Upside beats on specialty pharmacy volume drive multiple expansion.
Mature, cash-generative phase utilizing robust FCF ($7B-$10B) for aggressive share buybacks and targeted M&A.
Consolidation of specialty pharmacy and managed care services driving scale efficiencies.
Heightened legislative scrutiny on healthcare costs and PBM transparency.
Mature, cash-generative phase utilizing robust FCF ($7B-$10B) for aggressive share buybacks and targeted M&A.
Core holding suitable for mature compounder allocation.
Re-evaluate if operating margins compress toward 3.0% for 4 consecutive quarters or if total revenue turns negative.
Strong conviction Strong Buy driven by massive free cash flow, 16.2% ROE, and a valuation gap that implies -9.47% perpetual growth.
The market is fundamentally mispricing CI by extrapolating temporary PBM regulatory panic into permanent structural decline.
Strong conviction Strong Buy driven by massive free cash flow, 16.2% ROE, and a valuation gap that implies -9.47% perpetual growth.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Sweeping legislative changes target PBM spread pricing, crippling Evernorth's profitability and severely limiting cash for debt service.
Federal legislation permanently bans spread pricing and mandates full rebate pass-throughs across all books of business.
Unanticipated structural increase in utilization rates compresses medical loss ratios beyond historical norms.
Inability to service acquisition-related debt due to sustained margin compression, halting share repurchases.
The five developments that would weaken our investment case.
Margin compression within the services segment signals adverse PBM contract repricing and lost specialty pharmacy profitability. Weakening pharmacy margins cripple overall earnings expansion, limiting free cash flow necessary to support debt deleveraging and share repurchases.
Current:Above the 3.0% sector median as of 2026-05-12
Alert ifEvernorth operating margins compress below 3.0% over four consecutive quarters
Top-line contraction signals accelerating commercial membership losses or severe client attrition within pharmacy benefit management contracts. Shrinking revenue undermines fixed cost absorption and damages economies of scale, threatening top-line expansion assumptions and driving multiple compression.
Current:25.2% for the period ended 2024-12-31
Alert ifTotal revenue year-over-year growth falls below 0.0% over two consecutive quarters
Halting buybacks indicates critical cash flow strain caused by margin erosion and heavy debt service obligations. Terminating share repurchases eliminates a major driver of per-share earnings growth and signals elevated financial distress to equity markets.
Current:Active share repurchase program supported by operating cash flows as of 2026-05-12
Alert ifShare repurchase spending falls to $0 or is formally suspended over 1 or more fiscal quarters
Surging medical care costs indicate higher-than-modeled outpatient procedure volumes and medical inflation outstripping premium rate adjustments. Uncontrolled medical loss ratios directly impair underwriting income, forcing downward revisions to annual earnings expectations.
Current:Stable medical utilization trends within target corridors as of 2026-05-12
Alert ifMedical care ratio exceeds internal target corridors by more than 150 basis points over two consecutive quarters
Defection of major enterprise clients causes immediate loss of pharmacy claim volumes and specialty distribution scale. Large mandate losses degrade purchasing leverage against pharmaceutical manufacturers, structurally eroding service margins across the pharmacy services platform.
Current:Intact enterprise client relationships within Evernorth as of 2026-05-12
Alert ifLoss or contract termination of 1 or more Fortune 50 enterprise clients within a 12-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Evernorth takes specialty pharmacy market share, PBM regulatory fears ease, and the multiple re-rates toward the 13x peer median.
Robust $7B-$10B free cash flow generation persists. Forward EPS anchors valuation as the business navigates moderate regulatory changes without structural impairment.
Focus on Evernorth margin stability and Medical Care Ratio (MCR) trends. Upside beats on specialty pharmacy volume drive multiple expansion.
Warning level: Evernorth operating margins compress below 3.0% over four consecutive quarters. Margin compression within the services segment signals adverse PBM contract repricing and lost specialty pharmacy profitability. Weakening pharmacy margins cripple overall earnings expansion, limiting free cash flow necessary to support debt deleveraging and share repurchases.
Warning level: Total revenue year-over-year growth falls below 0.0% over two consecutive quarters. Top-line contraction signals accelerating commercial membership losses or severe client attrition within pharmacy benefit management contracts. Shrinking revenue undermines fixed cost absorption and damages economies of scale, threatening top-line expansion assumptions and driving multiple compression.
Warning level: Share repurchase spending falls to $0 or is formally suspended over 1 or more fiscal quarters. Halting buybacks indicates critical cash flow strain caused by margin erosion and heavy debt service obligations. Terminating share repurchases eliminates a major driver of per-share earnings growth and signals elevated financial distress to equity markets.
Warning level: Medical care ratio exceeds internal target corridors by more than 150 basis points over two consecutive quarters. Surging medical care costs indicate higher-than-modeled outpatient procedure volumes and medical inflation outstripping premium rate adjustments. Uncontrolled medical loss ratios directly impair underwriting income, forcing downward revisions to annual earnings expectations.
Warning level: Loss or contract termination of 1 or more Fortune 50 enterprise clients within a 12-month period. Defection of major enterprise clients causes immediate loss of pharmacy claim volumes and specialty distribution scale. Large mandate losses degrade purchasing leverage against pharmaceutical manufacturers, structurally eroding service margins across the pharmacy services platform.
| $174.27B |
| $180.03B |
| $195.19B |
| $244.38B |
| — |
| +11.9% |
| Gross profit | — | — | — | — | — | — |
| Operating income | $8.00B | $9.63B | $6.96B | $6.70B | — | -5.7% |
| Net income | $5.37B | $6.70B | $5.16B | $3.43B | — | -13.8% |
| EPS (diluted) | — | $21.30 | $17.39 | $12.12 | $22.18 | +1.4% |
| EBITDA | — | — | — | — | — | — |
| R&D | — | — | — | — | — | — |
| SG&A | $13.01B | $13.17B | $14.82B | $14.84B | — | +4.5% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Total assets | 155,881,000,000 |
|---|---|
| Cash | 7,550,000,000 |
| Total liabilities | 114,638,000,000 |
| Shareholders’ equity | 41,033,000,000 |
Point-in-time financial data used in the 2026-05-12 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 174.3B | — | 5.4B | 7.2B | 6B | 1.2B | 2.9B | — | 7.7B | 1.3B | 657M | — | — | — | — | 5.1B | 33.7B | 4.6% | — | 4.0% | — |
| 2022-12-31 | 180B | — | 6.7B | 8.7B | 7.4B | 1.3B | 2.9B | — | 7.6B | 1.4B | -2.6B | — | — | — | — | 5.9B | 31.1B | 5.3% | — | 6.1% | — |
| 2023-12-31 | 195.2B | — | 5.2B | 11.8B | 10.2B | 1.6B | 3B | — | 2.3B | 1.5B | -278M | — | — | — | — | 7.8B | 30.9B | 3.6% | — | 6.1% | — |
| 2024-12-31 | 244.4B | — | 3.4B | 10.4B | 9B | 1.4B | 2.8B | — | 7B | 1.6B | 1.1B | — | — | — | — | 7.6B | 32B | 2.7% | — | 6.3% | — |
CI trades at 8.6x forward earnings against a peer median of 13.1x; EV/EBITDA of 7.4x against a peer median of 9.1x; 6 peers.
| Immediate entry at current levels ($289.07), capitalizing on the extreme negative growth expectations priced into the stock. |
| CVS Health Corporation |
| 11.1x |
| 0.3x |
| 12.0x |
| 3.8% |
| 4.1% |
| ELV | Elevance Health Inc. | 13.1x | 0.4x | 9.1x | 12.1% | 5.3% |
| HUM | Humana Inc. | 18.0x | 0.2x | 7.6x | 6.3% | 4.7% |
| CNC | Centene Corporation | 12.6x | 0.2x | 7.1x | -26.0% | 5.1% |
